Avenue Therapeutics, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A, is in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Avenue Therapeutics itself, indicating that they are not preliminary proxy statements nor are they soliciting material under §240.14a-12. Furthermore, the company has confirmed that no filing fee is required for this submission.

Avenue Therapeutics, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A, is in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Avenue Therapeutics itself, indicating that they are not preliminary proxy statements nor are they soliciting material under §240.14a-12. Furthermore, the company has confirmed that no filing fee is required for this submission.